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Pharmacokinetic studies of the drugs administered to subjects with mechanical cholestasis are scarce. The purpose of the present study was to
examine the effects of bile duct ligation of 3 days (peak of elevation of serum bile acids and bilirubin) on the systemic and renal PAH clearance
and on the expression of cortical renal OAT1 and OAT3 in a rat model. PAH is the prototypical substrate of the renal organic anion transport
system. Male Wistar rats underwent a bile duct ligation (BDL rats). Pair-fed sham-operated rats served as controls. BDL rats displayed a
significantly lower systemic PAH clearance. Renal studies revealed a reduction in the renal clearance and in the excreted and secreted load of PAH
in BDL rats. The OAT1 protein expression in kidney homogenates was not modified, but it decreased in the basolateral membranes from BDL
rats. In contrast, OAT3 abundance in both kidney cortex homogenates and in basolateral membranes increased by 3 days after the ligation.
Immunocytochemical studies (light microscopic and confocal immunofluorescence microscopic analyses) confirmed the changes in the renal
expression of these transport proteins. The present study demonstrates the key role of OAT1 expression in the impaired elimination of PAH after 3
days of obstructive cholestasis.
© 2006 Elsevier B.V. All rights reserved.Keywords: p-aminohippurate; Cholestasis; Renal depuration; OAT1; OAT31. Introduction
Extrahepatic, mechanical cholestasis occurs in about 10% of all
patients suffering from cholelithiasis and in the majority of
neoplasms affecting the pancreas and the common bile duct [1].
Prolonged cholestasis may alter the liver function due to an impair-
ed uptake, changed biotransformation and secretion of compounds
as well as secondary abnormalities induced within the kidney [2,3].
Pharmacokinetic studies of drugs administered to subjects
with mechanical cholestasis are scarce [4]. Moreover, the
obtained results are often conflicting, possibly due to the use of
different species and interindividual differences.
The kidney and the liver play the major role in the elimination
of numerous potentially toxic xenobiotics, including drugs, to-⁎ Corresponding author. Suipacha 531, Rosario 2000, Argentina. Tel.: +54
341 4373787; fax: +54 341 4371992.
E-mail address: adtorres@fbioyf.unr.edu.ar (A.M. Torres).
0925-4439/$ - see front matter © 2006 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2006.05.011xins, and endogenous metabolites. In some cases, the loss of one
route of elimination can be compensated by the other [5]. It must
also bementioned that the impairment of liver or kidney functions
can cause syndromes characterized by an injury of the alternative
elimination organ [6,7].
In human beings and rats, extrahepatic cholestasis has been
shown to render the kidney susceptible to a variety of nephrotoxic
agents [6]. The pathophysiological cause of renal damage in the
course of bile flow impairment is still not well understood, even
though several phenomena, such as increased access of various
constituents into the kidney (bilirubin and bile salts) have been
suggested [6,7].
An impairment of the kidney function produces modifica-
tions in the renal elimination of drugs mediated by alterations in
the blood flow to the kidney, glomerular filtration, active tubular
secretion and passive tubular reabsorption [8].
The renal organic anion transport plays a critical role in pro-
tecting against the toxic effects of anionic substances, whether of
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stances from the blood principally via the organic anion trans-
porter mechanisms found in the apical and basolateral membrane
of renal epithelial cells. Several carrier proteins have been cloned
and are functionally characterized from both membrane domains
of rat kidneys [9–11]. The organic anion transporter 1 (OAT1) and
the organic anion transporter 3 (OAT3) support the exchange
organic anion/dicarboxylate transport in the basolateral mem-
branes from the proximal tubule cells [12–15]. Two members of
the multidrug resistance protein (MRP) family are located at the
apical membranes from the proximal tubule cells, MRP2 and
MRP4 [10,11,16,17]. The abovementioned four proteins mediate
the renal transport of several anionic substances, such as p-ami-
nohippurate (PAH), the prototypic organic anion commonly used
in experimental studies. An up-regulation of renalMRP2 has been
described at 1 and 3 days after bile duct ligation [18,19]. One day
of bile duct ligation is referred as an early stage of obstructive
cholestasis and 3 days of bile duct ligation is the period in which
serum bile acids and bilirubin levels reach the peak of elevation
[18–20]. MRP4 decreases at 3 days after bile duct ligation [21].
An increase in the urinary excretion of PAH has been con-
comitantly demonstrated with an increase in the abundance
of OAT1 in the kidney homogenates in the early phase of an
obstructive cholestasis [22].
The purpose of the present study was thus to examine the
systemic and renal PAH clearance and the role of cortical renal
OAT1 andOAT3 in response to 3 days of biliary obstruction in rats.
2. Materials and methods
2.1. Experimental animals
MaleWistar rats aged from 110 to 130 days old were used throughout the study
(380–410 g bodyweight). In order to perform surgical procedures the animalswere
anaesthetizedwith sulfuric ether. After an upper abdominal incisionwas performed
under sterile condition, the common bile duct was isolated and double-ligated close
to the liver hilus immediately below the bifurcation and cut between the ligatures
(BDL group). The controls then underwent a sham operation that consisted of
exposure, but not a ligation, of the common bile duct (Shamgroup). The abdominal
incision was then closed by single sutures. All studies were performed 3 days after
surgery. All animals were allowed free access to a standard laboratory chow and tap
water, and housed in a constant temperature and humidity environmentwith regular
light cycles (12 h) during the experiment. All animals were cared for in accordance
with the principles and guidelines for the care and use of laboratory animals [23].
2.2. Biochemical determinations
On the day of the experiment, blood was withdrawn from femoral artery of
Sham and BDL animals. The serum was separated by centrifugation (3000 rpm,
3min). These sampleswere used tomeasure total and direct bilirubin as parameters
indicative of hepatic function and urea serum levels as a parameter indicative of
global renal function. The above mentioned biochemical analyses were performed
using optimized spectrophotometric techniques, while employing commercial kits
(Wiener Laboratory).
2.3. Pharmacokinetic studies
These studies were done in a manner similar to those previously described
[22,24]. At 3 days after surgery, the animals were anaesthetized with sodium
thiopental (70 mg/kg b.w., i.p.). The femoral artery and the vein were both
catheterized to obtain samples and to administer test compound, respectively. A
single bolus of PAH (30 mg/kg b.w., aqueous solution, i.v.) was administered.Blood sampleswere obtained at 0–15min range time after the administration of the
PAH solution. The volume of blood samples was 50 μL. Eight blood samples were
removed from each rat at different times between 0 and 15 min. An equivalent
volume of isotonic saline solutionwas infused to restore the amount extracted in the
blood samples. Samples were centrifuged at 3000 rpm for 3 min, and the extracted
plasmas were frozen at −20 °C until analyzes.
At 15 min after PAH administration, a suprapubic incision was performed in
order to isolate the bladder. Both ureters and the urethra were ligated with extreme
care in order not to lose any urine. Thereafter, the bladder was removed and the
whole contents of urine were then obtained to measure the quantity of PAH.
The plasma concentration vs. time curves for PAH, for each individual animal,
were fitted with the PKCALC computer program [25]. The data were fitted to a
biexponential curve. The choice of the best fit was based on the determination of
coefficient values (R2) andF test [25,26].All fits hadR2 values >0.9. The following
equation was used to describe the biexponential concentration–time curves:
Cp¼Ae−at þ Be−bt
where Cp is PAH plasma concentration (mg/mL) at time t (min) after
administration; constant α represents the distribution from the central compartment
and β is an equilibrium constant reflecting the dynamics between k21 and K10 and
the slopes of each of the adjusted curves give their values. A and B represent the
initial values of the distribution and elimination components, respectively, extra-
polated from the y-axis intercept. The estimate parameters (α, β, A, B) were used to
solve the first-order rate constants of transfer from the central to peripheral
compartments (k12, k21) and the elimination rate constant from the central
compartment (K10) with classical equations. Derived parameters: area under curve
(AUC), total volume of distribution (VdT), volume of the central compartment
(VdC), volume of the peripheral compartment (VdP), steady-state volume of
distribution (Vdss), systemic clearance (Cls), elimination half-life (t1/2 β) were
calculated according to standard procedures for the compartmental analysis. Cls
was calculated as theDose/AUC. The formulas for calculating the different volume
of distribution were: VdT=Dose / [β×AUC], VdC=Dose/A+B, VdP=VdT
−VdC, Vdss=Cls×MDRT, MDRT (mean disposition residence time)=AUMC/
AUC, AUMC is the area under curve for the plot of the product of concentration
and time vs. the time from time zero to infinity. Concentration of PAH in plasma
and in urine was measured using the method described by Waugh and Beall [27].
2.4. Binding of PAH to plasma proteins
The binding of PAH to plasma proteins in Sham and BDL rats was
determined using an ultrafiltration apparatus (Centrifree, Amicon, Millipore
Corporation, Bedford, Mass) as previously described [24].
2.5. Renal excretion studies
These studies were performed as previously described [24,28–31]. Sham (n=4)
and BDL (n=5) rats were anaesthetized as described. Femoral vein and artery were
cannulated and a bladder catheter (3 mm i.d.) was inserted through a suprapubic
incision. A priming dose of inulin (30 mg/kg b.w.) and PAH (30 mg/kg b.w.) in
1.5 mL of saline solution was administered through the venous catheter. Then, a
solution containing inulin (12 g/L), PAH (12 g/L) and saline solution (9 g/L) was
infused through the venous catheter employing a constant infusion pump (Pump 22;
Harvard Apparatus, USA) at a rate of 1 mL/h/100 g b.w. After equilibrating for
45min, urinewas collected during two 20-min periods. Blood from the femoral artery
was obtained at themidpoint of each clearance period. The arterial blood pressurewas
estimated throughout the experimentswith amanometer inserted in the femoral artery.
The glomerular filtration rate (GFR) was calculated from the clearance of inulin, in
order to determine filtered load of PAH. The excreted, secreted and filtered loads of
PAH were calculated by conventional formulae for each animal. The PAH concen-
trations in the serum and urine were determined by the method of Waugh and Beall
[27] and the inulin concentrations were assayed by the procedure of Roe [32]. The
volume of urine was determined by gravimetry.
2.6. Preparation of basolateral membrane (BLM) from kidney cortex
The preparations of BLM from Sham and BDL rats were done by a modifi-
cation of themethod described by Jensen andBerndt [33] as previously reported by
Table 1
Pharmacokinetic parameters of PAH in Sham (n=7) and BDL (n=8) rats after a
single dose (30 mg/kg b.w., i.v.)
Sham BDL
AUC (mg/min/mL) 0.88±0.04 1.34±0.15*
Cls (mL/min/100 g b.w.) 3.46±0.21 2.44±0.25*
A (mg/mL) 0.207±0.016 0.205±0.021
B (mg/mL) 0.095±0.016 0.087±0.013
α (min−1) 1.35±0.11 0.82±0.07*
β (min−1) 0.128±0.012 0.083±0.008*
K10 (min
−1) 0.345±0.017 0.234±0.022*
k12 (min
−1) 0.612±0.062 0.378±0.064*
K21 (min
−1) 0.523±0.086 0.289±0.024*
t1/2 (β) (min) 5.67±0.48 8.88±0.85*
VdT (mL/100 g b.w.) 28.43±2.79 31.12±4.37
VdC (mL/100 g b.w.) 10.11±0.55 10.50±0.59
VdP (mL/100 g b.w.) 18.32±2.52 20.61±4.16
Vdss (mL/100 g b.w.) 23.29±1.92 25.16±3.47
The results are expressed as the means±SEM. (*) P<0.05.
AUC=area under curve; Cls=systemic clearance; constant α represent the
distribution from the central compartment and β is an equilibrium constant reflecting
the dynamics between k21 and K10; A and B represent the initial values of the
distribution and elimination components, respectively; K10=elimination constant
from the central compartment; t1/2(β)=elimination half-life (t1/2); VdT=total volume
of distribution; VdC=volume of the central compartment; VdP=volume of the
peripheral compartment; Vdss=steady-state volume of distribution.
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containing 250 mM sucrose, 5 mM Tris–HEPES pH 7.40 at a ratio of 12.5 mL/g
cortex wet weight. After four gentle strokes with the loose fitting pestle, the
suspension was homogenized further with a motor-driven teflon pestle (600 rpm/5
strokes) and spun down for 15 min at 1200×g. The supernatant was aspirated and
spun for 15 min at 22,000×g. The fluffy beige upper layer of the resulting pellet
(crude plasma membranes) was resuspended in about 1 mL of supernatant and
added to 19 mL of buffered sucrose. The membrane suspension was homogenized
gently through a 16-gauge gavage needle followed by the addition of 3.7 mL of
100% Percoll. The Percoll-membranes mixture was spun for 30 min at 39,250×g.
The top clear layer was discarded and the top-most dark band was removed. This
layer was composed primarily of basolateral membranes. BLMwere brought up in
KCl buffer (85mMKCl, 83mM sucrose, 2mMHEPES–Tris pH 7.40) at a ratio of
8 mL/g original cortex wet weight. Next, BLM were pelleted at 30,000×g for
30 min and washed three times with the KCl buffer. Finally, BLM were
resuspended in 300 μL of 250 mM manitol, 10 mM HEPES–Tris, pH 7.40.
Aliquots of the membranes were stored immediately at −70 °C until use (no more
than 2 weeks after membrane preparations). Each preparation represents cortical
tissue from four animals. Four preparations were obtained for each experimental
group. Protein quantification of samples was performed using the method of
Sedmak and Grossberg [34].
2.7. Electrophoresis and immunoblotting
Homogenates and basolateral membranes were boiled for 3 min in the
presence of 1% 2-mercaptoethanol/2% SDS (Sodium Dodecyl Sulphate).
Samples were applied to a 8.5% polyacrilamide gel, separated by SDS-PAGE,
and then electroblotted to nitrocellulose membranes. Membranes were stained
with Ponceau Red to confirm equal protein loading and transfer between lanes as
previously described [21,22,28–30]. The nitrocellulose membranes wereFig. 1. Mean plasma concentration-time profile of PAH (A) and Systemic clearance
of PAH (B) in Sham (n=7) andBDL (n=8) rats following a single 30mg/kg b.w., i.v.
dose of PAH. Results are expressed as the means±SEM. #P<0.05.incubated with 5% nonfat dry milk in phosphate-buffer saline containing 0.1%
Tween 20 (PBST) for 2 h. After being rinsed with PBST, the membranes were
then incubated overnight at 4 °C with a commercial rabbit polyclonal antibody
against rat OAT1 (1.25 μg /mL) and with commercial mouse monoclonal
antibody against human β-Actin (1.25 μg /mL) or with non-commercial rabbit
polyclonal antibody against rat OAT3 (at a dilution of 1:1000) and with
commercial mouse monoclonal antibody against human β -Actin (1.25 μg /mL).
The specificity of OAT3 antibody has been described elsewhere [15]. The
membranes were incubated for 1 h with a peroxidase coupled goat anti-rabbit
IgG (Bio-Rad) or with a peroxidase coupled sheep anti mouse IgG (Amersham)
after further washing with PBST. Blots were processed for detection using
commercial kit (Opti-4CN, Bio-Rad for OAT1 and ECL enhanced chemilumi-
nescence system, Amersham for OAT3). To investigate the specificity of the
bands, an absorption test was performed. The OAT1 peptide (1.25 μg /mL) or
OAT3 peptide (0.50 mg/mL) were added to the OAT1-antibody specific solution
or OAT3-antibody specific solution respectively and incubated for 2 h. Using
these preabsorbed antibodies,Western blot analyses were performed as described
above. A densitometric quantification of the Western blot signal intensity of
membranes was performed.Fig. 2. Amount of PAH in urine excreted during 15 min following a single dose
of PAH (30 mg/kg b.w., i.v.) in Sham (n=7) and BDL (n=8) animals. Results
are expressed as the means±SEM. #P<0.05.
Fig. 3. Renal clearance of PAH in Sham (n=4) and BDL (n=5) rats. Results are
expressed as the means±SEM. #P<0.05.
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Kidneys from Sham and BDL rats were briefly perfusedwith saline, followed
by perfusion with periodate–lysine–paraformaldehyde solution (0.01 M NaIO4,
0.075 M lysine, 0.0375 M phosphate buffer, with 2% paraformaldehyde, pH:
6.20), through an abdominal cannula. The kidneys slices were immersed in
periodate–lysine–paraformaldehyde solution at 4 °C overnight. The tissue was
embedded in paraffin. Paraffin sections were cut. After deparaffining, the
sections were incubated with 3% H2O2 for 15 min (to eliminate endogenous
peroxidase activity) and then with blocking serum for 30 min. The sections were
then incubated with non-commercial polyclonal antibodies against OAT1
(diluted 1:1000) or OAT3 (diluted 1:1000) overnight at 4 °C. The specificity
of both antibodies has been described elsewhere [15]. The sections were rinsed
with PBST.
2.9. Light microscopic analysis
The sections were incubated with biotinylated secondary antibody against
rabbit Immunoglobulin for 1 h (biotinylated Ig Multi-Link Biogenex). After
being rinsed with PBST, the sections were incubated for 30 min with horseradish
peroxidase (HRP)-conjugated streptavidin solution (Streptavidin/HRP complex
Multi-Link Biogenex). In order to detect HRP labeling a peroxidase substrate
solution with diaminobenzidine (0.05% diaminobenzidine in PBSTwith 0.05%
H2O2) was used. The sections were counterstained with hematoxylin before
being examined under a light microscope.
2.10. Confocal microscopic analysis
The sections were incubated with Alexa 488 fluorochrome-conjugated goat
anti-rabbit IgG, 1:1000 (Molecular Probes, Eugene, OR) overnight at 4 °C.Table 2
Body weight, kidneys weight, kidney/body weight ratio, plasma PAH
concentrations (PPAH), glomerular filtration rate (GFR), filtered, secreted and
excreted loads of PAH (FLPAH, SLPAH, ELPAH) in Sham (n=4) andBDL (n=5) rats
Sham BDL
Body weight (g) 342±18 367±7
Kidneys weight (g) 2.34±0.16 2.57±0.09
Kidney/Body weight ratio (×10− 3) 6.84±0.26 6.99±0.16
PPAH (μM) 295±28 376±63
GFR (mL/min/100 g b.w.) 0.858±0.074 0.515±0.058 *
FLPAH (μg/min/ 100 g b.w.) 40±4 35±5
SLPAH (μg/min/ 100 g b.w.) 169±10 140±6 *
ELPAH (μg/min/100 g b.w.) 209±13 175±10 *
The results are expressed as the means±SEM.
* P<0.05.Sections were washed with PBST and then mounted. Afterwards, they were
viewed on a Zeiss Axiophot microscope equipped with an epifluorescence
detector and a Bio-Rad MRC 1260 confocal imaging system.
Controls using preimmune serum, antiserum absorbed with excess synthetic
peptide (as described above), or omission of primary or secondary antibody
revealed no labeling.Fig. 4. Renal homogenates (50 μg proteins) (A) and basolateral membranes (40 μg
proteins) (C) from kidneys of Sham and BDL rats were separated by sodium
docecyl sulphate-polyacrylamide gel electrophoresis (8.5%) and blotted onto
nitrocellulose membranes. OAT1 was identified using commercial polyclonal
antibodies as described in Materials and methods. Densitometric quantification of
OAT1 Western immunoblotting from renal homogenates (B) and basolateral
membranes (D). The results are expressed as percentage, normalized for the β actin
density. The Sham levels were set at 100%. Each column represents the mean±
SEM from experiments carried out in four different preparations for each
experimental group. #P<0.05.
Fig. 5. Immunocytochemistry for OAT1. (A and B) Immunoperoxidase in the renal cortex of Sham (A) and BDL rats (B). Serial sections from each rat kidney were
stained using a non-commercial anti-rOAT1 antibody (crude immune serum). OAT1 labeling was seen at the basolateral domains of proximal tubule cells. In BDL rats,
it can be seen that OAT1 labeling in BLM is greatly reduced. These figures are representative of typical samples from four rats. Magnification ×400. (C and D)
Immunofluorescence localization of OAT1 in the renal cortex of Sham (C) and BDL rats (D). Serial sections from each rat kidney were stained using a non-commercial
anti-rOAT1 antibody (crude immune serum). In BDL rats, it can be seen OAT1 labeling throughout the cytoplasm in the proximal tubules, whereas the labeling of
BLM was greatly reduced. These figures are representative of typical samples from four rats. Magnification ×400.
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Histopathology of kidneys was performed after fixing in 10% neutral
buffered formaldehyde solution for 4 h and embedding in paraffin, then 4 μm
thick sections were processed for routine staining with hematoxylin and eosin,
or stained with hematoxilin and PAS.
2.12. Materials
Chemicals were purchased from Sigma (St. Louis, MO, USA) and were
analytical grade pure. The polyclonal antibodies against OAT1, monoclonal
antibodies against β-actin and the OAT1 peptide for Western blotting were
purchased from Alpha Diagnostic International (San Antonio, TX, USA). The
polyclonal antibody against OAT1 for immunocytochemical studies and
polyclonal antibody against OAT3 and the OAT3 peptide for both Western
and immunocytochemical studies were non-commercial [15].
2.13. Statistical analysis
The statistical analysis was performed using the unpaired t-test. When
variances were not homogeneous a Welch's correction was employed. P values
of less than 0.05 were considered significant. The values are expressed as the
means±standard error (SEM). For these analyses, a GraphPad software was
used. For densitometry of immunoblots, samples from kidneys of BDL rats were
run on each gel with corresponding Sham kidneys. The abundance of OAT1 and
OAT3 in the samples from the experimental animals was calculated as percentage
of the mean Sham control value for that gel.3. Results
Total bilirubin concentration in BDL rats increased to 71.34±
4.31 mg/L from 2.51±0.36 mg/L observed in Sham group,
whereas direct bilirubin level increased from 1.30±0.24 mg/L in
Shamanimals to 66.85±4.16mg/L inBDLones. Lightmicroscopy
only showed significant renal morphological alterations in PAS
stained kidneys. In BDL rats, the kidney appears congestive,
predominantly in themedulla. The tubular epithelium is less tall and
shows apical extrusions and its foldings are less conspicuous. The
cytoplasm presents a PAS (+) granularity. The tubules are mode-
rately dilated, containing intraluminal proteinaceous, eosinophilic
and acidophylic, material. These results are similar to those
described by Wójcicki et al. [4].
On the other hand, no significant difference in the urea serum
levels (g/L) was observed between the Sham-operated and BDL
animals (0.40±0.02 vs. 0.41±0.02 respectively).
Themean plasma concentration-time profiles for PAH in Sham
and BDL rats are shown in Fig. 1A. The higher plasma con-
centrations of PAH in BDL group were displayed during the
distribution and elimination phases. BDL rats displayed a
significant higher area under the curve and therefore a significant
lower systemic clearance for PAH (Fig. 1B). The constant α
(which represents the distribution from the central compartment),
678 A. Brandoni et al. / Biochimica et Biophysica Acta 1762 (2006) 673–682the constant β (which is an equilibrium constant reflecting the
dynamics between k21 and K10), the rate constants of transfer
from central to peripheral compartments (k12, k21) and the
elimination rate constant from the central compartment (K10) were
all decreased in BDL rats, thus indicating the impairment in theFig. 6. Renal homogenates (50 μg proteins) (A) and basolateral membranes
(40 μg proteins) (C) from kidneys of Sham and BDL rats were separated by
sodium docecyl sulphate-polyacrylamide gel electrophoresis (8.5%) and blotted
onto nitrocellulose membranes. OAT3 was identified using non-commercial
polyclonal antibodies as described in Materials and methods. The densitometric
quantification of the OAT3 Western immunoblotting from renal homogenates
(B) and basolateral membranes (D). Results are expressed as percentage,
normalized for the β actin density. The Sham levels were set at 100%. Each
column represents the mean±SEM from experiments carried out in four
different membrane preparations for each experimental group. #P<0.05.rates of distribution and elimination of PAH (see Table 1). The
distribution volumes were not significantly different between the
Sham-operated and BDL animals as it is shown in Table 1.
A statistically significant decrease was observed in the
quantity of PAH excreted in urine during 15 min (Fig. 2).
The percentage of unbound PAH to plasma proteins was
higher in BDL rats than in the Sham ones (100±0.1 (n=4) vs.
95.3±1.4 (n=4), P<0.05, respectively). The values obtained
for the Sham rats are similar to those previously reported [24].
Renal studies showed a decrease in the renal clearance of PAH in
BDL rats as it is shown in Fig. 3. The excreted, secreted and filtered
loads of PAH were lower in BDL rats compared with Sham rats,
even though for the filtered load of PAH the difference did not reach
the level of significance (Table 2). The glomerular filtration rate
from jaundiced group was significantly lower in comparison with
Sham group as it is also shown in Table 2. As a result, excreted load
of PAH was lower in the BDL rats as consequence of the decrease
in the secreted load of this organic anion.
Kidney cortex homogenates and basolateral membranes from
Sham and BDL animals were subjected to immunoblot analyses
for OAT1 protein. Fig. 4 shows no difference between the groups
in the homogenates OAT1 expression. On the other hand, a
lower abundance of OAT1 was observed in the basolateral
membranes from BDL rats in comparison to the Sham rats. The
OAT1 protein disappeared when the antibody was preabsorbed
to the synthetic antigen peptide (data not shown).
Immunocytochemistry using horseradish peroxidase-conju-
gated secondary antibodies for light microscopy confirmed the
reduced OAT1 expression in basolateral plasma membranes
from BDL rats (Fig. 5B). The Sham rats showed an abundant
OAT1 labeling in basolateral domains (Fig. 5A). To further
characterize the distribution of OAT1 labeling in the proximal
tubule cells, immunofluorescence was used (Fig. 5C and D).
Confocal immunofluorescence studies also revealed a decrease
in OAT1 labeling in basolateral plasma membranes and allowed
a better appreciation of a punctuate labeling for OAT1, which
was distributed widely throughout the cytoplasm in the kidneys
from the BDL rats demonstrating the cellular internalization of
this carrier protein.
The Western blotting findings of the kidney cortex homo-
genates and BLM from Sham and BDL rats showed signals for
OAT3. In Fig. 6 it is possible to observe that the OAT3 abun-
dance significantly increased in the kidney cortex homogenates
and in the BLM from BDL rats in comparison to Sham ones.
These signals were not observed when the antibody was
preabsorbed with the OAT3 peptide (data not shown).
Immunocytochemistry studies showed staining for OAT3 in
many parts of the nephron such as the proximal tubule (S1, S2
and S3), the distal and the collecting duct as it has been
previously described [15]. Sham rats showed OAT3 labeling in
basolateral membrane domain and inside the cytoplasm of renal
tubular cells (Fig. 7A). Increased labeling was seen in the
basolateral membranes of the tubules from kidneys of BDL rats
(Fig. 7B). Immunofluorescence microscopy showed the baso-
lateral membrane localization of OAT3 and a better detection of
the intracellular localization (Fig. 7C). An important increase of
OAT3 in basolateral membranes was observed in the cortex from
Fig. 7. Immunocytochemistry for OAT3. (A and B) Immunoperoxidase in the renal cortex of Sham (A) and BDL rats (B). Serial sections from each rat kidney were
stained using a non-commercial anti-rOAT3 antibody. OAT3 labeling was seen at the basolateral domains of tubule cells and inside the cells. In BDL rats, it can be seen
an increased OAT3 labeling in BLM. These figures are representative of typical samples from four rats. Magnification ×400. (C and D) Immunofluorescence
localization of OAT3 in the renal cortex of the Sham (C) and BDL rats (D). Serial sections from each rat kidney were stained using a non-commercial anti-rOAT3
antibody. OAT3 labeling was seen at the basolateral domains of tubule cells and inside the cells. In the BDL rats, it could be seen as an increased OAT3 labeling in the
BLM of tubular cells. These figures are representative of typical samples from four rats. Magnification ×400.
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from an immunoblotting study.
4. Discussion
A large and diverse number of organic anions, or weak organic
acids that exist as anions at physiological pH, are secreted by
mammalian renal tubules. Substrates for the renal organic anion
transport system include weak acids that have a net negative
charge on carboxyl or sulfonyl residues at physiological pH [9–
11]. Although this system secretes a number of endogenous
compounds, it is generally accepted that is particularly important
in secreting numerous exogenous compounds, including phar-
macologically active substances, industrial and environmental
toxins, and plant and animal toxins [9–11]. The transport of these
substances across the basolateral membrane of renal epithelial
cells is energetically uphill [9–11]. Molecular candidates for each
of the organic anion transport process have been cloned, including
OAT1 and OAT3 that serve as organic anion/dicarboxylate
exchangers at the basolateral membrane of renal proximal tubulecells [9–15]. An unexplored aspect of OATs regulation concerns
the body's response to disease states. We have recently demons-
trated alterations in renal OAT1 and OAT3 expression in different
experimental models in rats such as bilateral ureteral obstruction
[28,29], arterial calcinosis [31], and chronic renal failure [30].
However, little is known about the regulation of these transporters
after the early phase of extrahepatic cholestasis.
Acute jaundice due to bile duct obstruction is defined as the
retention of bile and bile components. Biliary excretion of organic
anions is a critical physiologic function of the liver. However, in
obstructive jaundice, in which the biliary transport is impaired,
adaptive mechanisms involving protein expression may permit
urinary excretion of those potentially toxic compounds [1,4].
There are limited data on the pharmacokinetics of drugs in sub-
jects with biliary obstruction.
Performing bile duct ligation as a well-established model of
cholestasis, we have determined an increase in the systemic
clearance of PAH associated to an increase in the abundance of
OAT1 in renal cortex homogenates in rats at 21 h after bile duct
ligation (early phase of acute extrahepatic cholestasis) [22]. The
680 A. Brandoni et al. / Biochimica et Biophysica Acta 1762 (2006) 673–682aim of the present study was to examine the systemic and the
renal clearance of PAH and the expression of both OAT1 and
OAT3 in homogenates and basolateral membranes from rat renal
cortex after a period of 3 days of bile duct obstruction (it has been
well documented that serum bile salts and bilirubin levels reach
the peak of elevation after 3 days of ligation [18–20]).
The clearance of a drug may be defined in a general way as “a
proportionality constant describing the relationship between a
substance's rate of transfer, in amount per unit time, and its
concentration, in an appropriate reference fluid” [35]. The current
study shows that rats at 3 days after bile duct ligation exhibit an
increase in the area under the PAH plasma concentration–time
curve and therefore, a statistically different decrease in the total
body clearance. Furthermore, the total body clearance can be
expressed as the product of the elimination rate microconstant
(K1-0) from the central compartment and the volume of such
compartment. This last parameter was not modified in rats with
extrahepatic cholestasis. On the other hand, a decrease was
observed in K1-0 in bile duct ligated rats as compared with Sham
ones. K1-0 is influenced by variables that participate in the
elimination of the drug from the central compartment, such as
metabolization, renal and biliary excretion. As PAH metaboliza-
tion and biliary excretion is negligible, the decrease of K1-0
observed in treated animals indicates a lower renal elimination of
this organic anion. In this connection, rats subjected to bile duct
ligation for 3 days showed a diminished renal PAH clearance. The
decrease in renal PAH elimination is accounted for the diminished
secreted load of the drug, since the filtered load of PAH was not
modified in the BDL group.
In this cholestatic model, the OAT1 expression significantly
decreased in the basolateral membranes from kidneys after 3 days
of bile duct ligation. In addition to immunoblotting, immunocy-
tochemical techniques corroborates the decrease in the basolateral
membranes expression of OAT1 together with a significantly
enhanced immunocytochemical staining for OAT1 in the
cytoplasm of proximal tubule cells of BDL kidneys, which
might suggest an internalization of membrane transporters or an
inhibition in the recruitment of preformed transporters into the
membranes.
It has been demonstrated that OAT1, when heterologously
expressed in oocytes or mammalian cells, is inhibited by more or
less selective PKC activators [36,37]. In this connection, it was
demonstrated byWolff et al. [38] that PKC induces human OAT1
down-regulation through carrier retrieval from the cell membrane
and it does not involve phosphorylation. It is well known that
angiotensin II [39] modulates the renal proximal tubule function
via activation of PKC. Although the role of the renin–angiotensin
system in the BDL model remains controversial [7], some
humoral factors including angiotensin II induced by the 3 days
BDLmay induce the activation of PKC.Moreover, bile acids and
high bilirubin levels can activate PKC [40,41]. It has been de-
monstrated that 3 days of bile duct ligation is the period in which
serum bile acids and bilirubin levels reach the peak of elevation.
We therefore postulate that the peak of elevation of bile acids and
bilirubin can also trigger PKC activation. This PKC activation
may cause the phosphorylation of caveolin-2, which may induce
internalization of caveolae with OAT1 protein anchored withcaveolin as has been recently suggested by Kwak et. al. [42]. This
OAT1 downregulation (30%) was associated with a concomitant
decrease of renal and systemic PAH clearance (40% and 30%
respectively). The medium PAH plasma concentrations reached
during the renal clearance infusion studies were 295 μM and
376 μM for the Sham and BDL rats respectively. The OAT1
mediated uptake of PAH is saturable with apparent Michaelis
constants ranging 15 to 70 μM for rat OAT1 [13]. Therefore, PAH
concentrations that we obtained in our “in vivo” experiments were
sufficiently higher than the reported Km of rat OAT1. The dimi-
nished secreted load of PAH measured under saturating con-
ditions was in part account for the lower number of OAT1 protein
units observed, by immunoblot technique, in basolateral plasma
membranes fromBDL kidneys. The opposite was observed in the
early phase of extrahepatic cholestasis where an increase of 30%
of OAT1 abundance was associated with a similar increase in
PAH clearance [22]. The differences observed in OAT1 abun-
dance between 21 and 72 h of bile duct ligation remain to be
explained. The increased OAT1 abundance observed in the early
phase of extrahepatic cholestasis suggests a transient up-regula-
tion similar to those described for renal OCT1 in cholestatic rats
[43]. Maybe, different levels of various cytokines and growth
factors which may affect gene transcription might be involved
[44].
In contrast with OAT1, OAT3 expression increased both in
homogenates and BLM from BDL kidneys. OAT3 is found in
various cells and in all parts of the nephron, whereas OAT1 is
confined to proximal tubules. The human and rat OAT3 transport
PAH with relatively high affinity (87 and 65 μM respectively)
[14,45], similarly to OAT1. On the contrary, estrone sulfate,
cholate, and taurocholate are substrates for OAT3 and not for
OAT1 as it has been demonstrated using Xenopus laevis oocytes
[12,14,45,46],MDCKcells [47] andOAT3 knockoutmice [48]. It
is therefore possible that the over-expression of OAT3 does not
compensate for the down-regulation of OAT1 regarding PAH
transport because in this pathology the high plasma levels of bile
acids might compete with PAH for OAT3 transport. Moreover,
bile acids have been shown to regulate the expression of several
genes involved in bile salt transport [49–51]. It is possible that
high bile acids levels up-regulate OAT3 expression without
affecting the OAT1 expression, being this another example of
substrate specific regulation. The up-regulation of OAT3 protein
in rat kidney in the present study is thus consistent with the
adaptation to increased plasma bile acid levels that result from
obstructive cholestasis, thus providing an additional alternative
pathway for bile salt elimination.
MRP2 up-regulation has been described in the kidneys from rats
with bile duct obstruction of 1 and 3 days [18,19]. On the other
hand, renal MRP4 was down-regulated at 3 days after biliary
obstruction [21]. Therefore, the protein expression of the luminal
(MRP2 and MRP4) and basolateral organic anions renal trans-
porters (OAT1 and OAT3), which all transport PAH, are differently
regulated in extrahepatic biliary obstruction, thus indicating that
different roles are played by these transporters in the pathogenesis
of cholestasis. Tubular secretion is a vectorial transcellular transport
system consisting of basolateral entry into the epithelial cells and
secretion across the brush border membranes. Defects in either of
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of ionic drugs. In the present study, the tubular secretion of PAH
was markedly reduced, thus suggesting a predominant role of
OAT1 in this process.
It is important to mention that to predict the efficacy of a drug
in vivo, it is critical to account for plasma protein binding
because it determines the availability of the free drug, its half-
life, and its subsequent renal elimination. Bow et al. [52] recently
demonstrated that the degree of binding affinity for albumin to
substrate determines whether or not a compound is actively
secreted or reabsorbed by organic anion transporters. The
common high unbound fraction of PAH increased from 95% in
Sham rats to 100% in BDL rats. Since the bile acids and bilirubin
plasma levels significantly increased in this experimental model,
hence the binding sites on albumin for such hydrophobic anions
might thus be occupied in the jaundiced rat, thereby increasing
even more the unbound fraction of PAH.
The increase in the unbound fraction of PAH in BDL rats did
not modify the distribution volumes of this anion. Nevertheless,
in BDL rats there is a higher free concentration of PAH available
for organic anion transporters, the OAT1 downregulation leads
to a decrease in renal and systemic PAH clearance, thereby again
stressing the main role of OAT1 in PAH excretion.
The present study stresses, once more, the important role of
OAT1 expression in the renal elimination of PAH, indepen-
dently of renal OAT3 expression. In this connection, it has been
reported that a decrease of OAT1 abundance in BLM is
associated with a decrease in PAH renal elimination in chronic
renal failure [30], in obstructive nephropathy [28,29] and in
response to 3 days of bile duct ligation, as it is shown in the
present study. Meanwhile, OAT3 abundance in renal BLM has
not changed, decreased or increased, respectively, in these three
experimental models of pathologies [28–30]. Moreover, the
increased renal excretion of PAH and furosemide is concom-
itantly observed with an increase in OAT1 and no changes in
OAT3 abundance in BLM from rats with an early stage of
extrahepatic cholestasis [22,53]. Accordingly, Eraly et al. [54]
recently reported, using the OAT1 knock out mouse model, that
regardless of the potential contribution of OAT3, the bulk of
organic anion transport during the basolateral uptake step of the
classical pathway is mediated by OAT1.
As highly accumulated anionic drugs observed during
cholestasis may cause general body deterioration, the molecular
mechanism(s) involved in the differential renal regulation of
MRP2, MRP4, OAT3 and OAT1 expression should therefore be
elucidated to prevent the occurrence of drug-induced toxicity
due to this pathology.
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